Development of Primer-Special TaqMan® PCR: A Novel SNP Detection Method to Detect CYP2C9*3 in South Chinese

ISSN： 1177-1062

Source： Molecular Diagnosis & Therapy, Vol.14, Iss.2, 2010-04, pp. : 123-129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background CYP2C9*3 (1075A/C) is an inherited single nuclear polymorphism (SNP) of cytochrome P450 (CYP) 2C9, which affects the activity of the enzyme. In vitro studies with several drugs have indicated that the CYP2C9*3 variant has an impaired capacity for drug metabolism. Therefore an efficient detection assay for this mutation may be important for clinical dose adjustment.Objective The aim of this work was to develop an appropriate tool for detection of the CYP2C9*3 polymorphism in the clinical laboratory.Study Design The previously described TaqMan® mismatch amplification mutation assay (TaqMAMA) was modified to a primer-special (PS)-TaqMan® PCR to satisfy the high-throughput requirements of a clinical laboratory. 404 genomic DNA samples from South Chinese individuals were genotyped to test the detection system. The results were checked by bi-directional sequencing.Results PS-TaqMan® PCR could correctly genotype the CYP2C9 allele from a genomic template at a concentration of 1 × 104 to 1 × 1011 copies/PCR. Among the 404 genomic DNA samples, 24 heterozygotes and 380 wild-type homozygotes were detected and confirmed by bi-directional sequencing.Conclusion PS-TaqMan® PCR was successfully developed for CYP2C9*3 detection. This efficient, reliable, high-throughput tool could satisfy the requirements of a clinical laboratory test.